In summary, our study indicates that TRIB3 is a reasonable molecular target for the treatment of high MYC-expressing lymphoma and that interruption of the MYC-TRIB3 and MYC-MAX interactions has therapeutic potential for this lymphoma. Here, MAX is linked to lymphoma.